Disclosures for "Efficacy and Safety of Novel Diabetes Drugs for Stroke Prevention: Systematic Review, Meta-analysis, and Meta-regression"
-
Ms. Barry has nothing to disclose.
-
Dr. Trifan has nothing to disclose.
-
Dr. Testai has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. Dr. Testai has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Swanson Martin & Bell, LLP. Dr. Testai has received publishing royalties from a publication relating to health care.